Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders

Keyphrases

• Chronic Kidney Disease 100%
• Peripheral Neuropathy 100%
• Peripheral Nerve Defect 100%
• Pharmacotherapeutic Interventions 100%
• Etiology 50%
• In Cancer 50%
• Quality of Life 50%
• Survivors 50%
• Diabetic Neuropathy 50%
• Obesity 50%
• Metabolic 50%
• High Prevalence 50%
• Experimental Therapeutics 50%
• Survival Rate 50%
• Therapeutic Agents 50%
• Clinical Treatment 50%
• Gangrene 50%
• Amputation 50%
• Neuropathy 50%
• Chronic Inflammatory Demyelinating Polyradiculoneuropathy 50%
• Guillain-Barré Syndrome 50%
• Diabetic Kidney Disease 50%
• Autoimmune Neuropathy 50%
• Metabolic Conditions 50%
• Physical Disability 50%
• Socioeconomic Burden 50%
• Chemotherapy-induced Peripheral Neuropathy 50%
• Immune Etiology 50%
• Treatment Complications 50%
• Loss of Sensation 50%
• Uremic Neuropathy 50%

Medicine and Dentistry

• Neuropathy 100%
• Immunity 33%
• Prevalence 33%
• Chronic Kidney Disease 33%
• Weakness 16%
• Quality of Life 16%
• Malignant Neoplasm 16%
• Sensation 16%
• Diabetes 16%
• Survival Rate 16%
• Therapeutic Agent 16%
• Gangrene 16%
• Amputation 16%
• Polyradiculoneuropathy 16%
• Diabetic Neuropathy 16%
• Chemotherapy-Induced Peripheral Neuropathy 16%
• Physical Disability 16%
• Experimental Therapeutic 16%
• Complication of Treatment 16%
• Uremic Polyneuropathy 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Neuropathy 100%
• Prevalence 33%
• Chronic Kidney Failure 33%
• Weakness 16%
• Malignant Neoplasm 16%
• Syndrome 16%
• Diabetic Neuropathy 16%
• Experimental Therapeutic 16%
• Survival Rate 16%
• Gangrene 16%
• Polyradiculoneuropathy 16%
• Chemotherapy-Induced Peripheral Neuropathy 16%
• Uremic Polyneuropathy 16%
• Physical Disability 16%